ResMed Posts Strong Q2 Growth, Eyes GLP-1 Tailwind and AI-Driven Innovation
ResMed reports robust revenue and margin expansion in its fiscal Q2 2026, driven by strong device and mask sales. Management highlights strategic investments in AI-powered patient tools and views GLP-1 medications as a potential catalyst for future demand.